10 Jun

How Analysts Rate Tandem Diabetes Care and Insulet

WRITTEN BY Margaret Patrick

Evolving insulin delivery landscape

Until the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson (JNJ). However, in October 2017, Johnson & Johnson issued a press release announcing intentions to exit the insulin pump market. The company also offered to transfer around 90,000 of its patients using Animas insulin pumps to Medtronic’s pump.

Although Medtronic was the major beneficiary of Johnson & Johnson’s exit, this event coupled with a continuous focus on innovation has driven uptake of insulin pumps offered by smaller diabetes MedTech players such as Tandem Diabetes Care (TNDM) and Insulet (PODD).

Tandem Diabetes Care rallied by 1,394.88% in 2018 from $2.54 on January 2 to $37.97 on December 31. The stock has been already up by 88.83% in 2019 YTD and closed at $71.70 on June 7. Insulet Corp rose by a lower 14.96% from $69.00 on January 2 to $79.32 on December 31. However, the stock is also 40.46% up in 2019 YTD and closed at $111.41 on June 7. To evaluate which of the two is a better pick in the long run, we take a look at the various pros and cons of both the companies.

Analysts’ recommendations and Target price

The consensus recommendation for both Tandem Diabetes Care and Insulet Corp is “buy.” Wall Street analysts expect an upside potential of 11.58% for Tandem Diabetes Care based on the company’s closing price on June 7. Analysts have gradually increased the company’s 12-month consensus target price from $67.27 in February to $72.00 in March to $78.92 in April to $80.00 in May. The highest and lowest target estimate is 100 and 70, respectively. Out of 13 analysts covering Tandem Diabetes Care, four recommend a “strong buy,” six recommend a “buy,” and three recommend a “hold.”

Wall Street analysts expect a downside potential of 4.07% for Insulet Corp based on the company’s closing price on June 7. Analysts have gradually increased the company’s 12-month consensus target price from $103.73 in February to $104.40 in March to $106.56 in April to $106.88 in May. The highest and lowest target estimate is 118 and 97, respectively.

Out of 18 analysts covering Insulet, seven recommend a “strong buy,” seven recommend a “buy,” and four recommend a “hold.”

Latest articles

Tortoise Capital Advisors bought 9.5 million Kinder Morgan shares in Q3. That was the biggest addition among the company’s top 10 institutional investors.

Although near-term weakness exists in the cannabis stocks, we expect Cannabis 2.0 products or cannabis-derived products could act as a catalyst.

The US, Saudi Arabia, and Russia are the world’s top three crude oil producers. Let’s take a look at the world’s top oil players by production volumes.

Tesla’s Model Y is gearing up to enter the EV market next summer. Ford heated up this space with its announcement of the Mustang Mach-E launch in late 2020.

Yesterday, Comcast (CMCSA) rose 0.5% and closed at $44.81, with a market capitalization of $203.9 billion. But can you expect a further rise?

Advanced Micro Devices (AMD) is one of the best-performing semiconductor stocks of 2019, beating 100% year-to-date growth.